What is a stock summary page? Click here for an overview.
Business Description
Penumbra Inc
NAICS : 339999
SIC : 3841
ISIN : US70975L1070
Description
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.52 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | 5.19 | |||||
| Interest Coverage | 84.78 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 18.51 | |||||
| Beneish M-Score | -2.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.5 | |||||
| 3-Year EBITDA Growth Rate | 78.2 | |||||
| 3-Year EPS without NRI Growth Rate | 151.2 | |||||
| 3-Year Book Growth Rate | 5.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 39.75 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.66 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.03 | |||||
| 9-Day RSI | 61.67 | |||||
| 14-Day RSI | 57.9 | |||||
| 3-1 Month Momentum % | 19.7 | |||||
| 6-1 Month Momentum % | 50.31 | |||||
| 12-1 Month Momentum % | 28.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.01 | |||||
| Quick Ratio | 3.44 | |||||
| Cash Ratio | 2.15 | |||||
| Days Inventory | 325.52 | |||||
| Days Sales Outstanding | 57.34 | |||||
| Days Payable | 26.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | 0.97 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.2 | |||||
| Operating Margin % | 7.22 | |||||
| Net Margin % | 1.17 | |||||
| FCF Margin % | 12.33 | |||||
| ROE % | 1.21 | |||||
| ROA % | 0.91 | |||||
| ROIC % | 5.33 | |||||
| 3-Year ROIIC % | 32.18 | |||||
| ROC (Joel Greenblatt) % | 2.58 | |||||
| ROCE % | 1.4 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 841.85 | |||||
| Forward PE Ratio | 78.14 | |||||
| PE Ratio without NRI | 144.34 | |||||
| Shiller PE Ratio | 572.46 | |||||
| PS Ratio | 9.46 | |||||
| PB Ratio | 9.57 | |||||
| Price-to-Tangible-Book | 11.26 | |||||
| Price-to-Free-Cash-Flow | 77.31 | |||||
| Price-to-Operating-Cash-Flow | 67.6 | |||||
| EV-to-EBIT | 551.75 | |||||
| EV-to-Forward-EBIT | 57.41 | |||||
| EV-to-EBITDA | 248.06 | |||||
| EV-to-Forward-EBITDA | 53.52 | |||||
| EV-to-Revenue | 8.94 | |||||
| EV-to-Forward-Revenue | 7.89 | |||||
| EV-to-FCF | 72.77 | |||||
| Price-to-GF-Value | 1.05 | |||||
| Price-to-Projected-FCF | 10.31 | |||||
| Price-to-Graham-Number | 8.5 | |||||
| Price-to-Net-Current-Asset-Value | 19.37 | |||||
| Earnings Yield (Greenblatt) % | 0.18 | |||||
| FCF Yield % | 1.34 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:PEN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Penumbra Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,194.615 | ||
| EPS (TTM) ($) | 0.34 | ||
| Beta | 0.78 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.48 | ||
| Volatility % | 36.68 | ||
| 14-Day RSI | 57.9 | ||
| 14-Day ATR ($) | 9.594112 | ||
| 20-Day SMA ($) | 277.373 | ||
| 12-1 Month Momentum % | 28.01 | ||
| 52-Week Range ($) | 148 - 310 | ||
| Shares Outstanding (Mil) | 38.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Penumbra Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Penumbra Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Penumbra Inc Frequently Asked Questions
What is Penumbra Inc(PEN)'s stock price today?
The current price of PEN is $286.23. The 52 week high of PEN is $310.00 and 52 week low is $148.00.
When is next earnings date of Penumbra Inc(PEN)?
The next earnings date of Penumbra Inc(PEN) is 2025-05-07 Est..
Does Penumbra Inc(PEN) pay dividends? If so, how much?
Penumbra Inc(PEN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers